Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
First-in-class guanylate cyclase agonistAstraZeneca today announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C). Linzess is a first-in-class guanylate cyclase‐C (GC‐C) receptor agonist and the approval offers an important treatment option for adult patients in China. The NMPA approval is based on a Phase III global, multicentre, clinical trial, jointly conducted by